Biotech Values

[TwoNE1]

AFMD - Affimed Announces Pricing of Public Offering of Common Stock

Heidelberg, Germany February 13, 2018 - Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the pricing of its previously announced public offering of 11,500,000 of its common shares at a public offering price of $2.00 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 common shares at the public offering price less underwriting discounts. After deducting the underwriting discounts, the net proceeds of the public offering are expected to be approximately $21.6 million. The offering is expected to close on or about February 15, 2018, subject to customary closing conditions.

Jefferies LLC and Wells Fargo Securities, LLC are acting as joint book-running managers.

source: https://finance.yahoo.com/news/affimed-announces-pricing-public-offering-080109395.html

PRELIMINARY PROSPECTUS SUPPLEMENT
http://services.corporate-ir.net/SEC/Document.Service?id=P3VybD1hSFIwY0RvdkwyRndhUzUwWlc1cmQybDZZWEprTG1OdmJTOWtiM2R1Ykc5aFpDNXdhSEEvWVdOMGFXOXVQVkJFUmlacGNHRm5aVDB4TWpBME5EQTRPQ1p6ZFdKemFXUTlOVGM9JnR5cGU9MiZmbj1BZmZpbWVkVGhlcmFwZXV0aWNzQUdfNDI0QjVfMjAxODAyMTIucGRm